BioCurex, Inc.(fka BOCX)

[Kag]

In a document dated March 31, 2005 and titled "Biocurex Inc. Management Discusses Licensing Agreement" the following is stated:

"Third: BioCurex has also retained all rights for detection of cancer cells on tissue sections (Histo-RECAF(TM)) as well as any applications using RECAF(TM) for tumor imaging, therapy or vaccination."

The above quote, from BioCurex management, would have been important information to have included, for the consumption of investors, in the joint BioCurex/Abbott press release at the time of the announcement of the Abbott deal. Why wasn't it included, and why were the same exact words "Under terms of the licensing agreement, Abbott obtains worldwide, semi-exclusive rights to commercialize products using BioCurex's RECAF technology" used again in BioCurex's November 9, 2005 SEC Form SB-2/A filing? Perhaps Abbott wrote the RECAF deal press release, and there has since been a lack of attention to detail concerning this matter on the part of BioCurex. It is my opinion that BioCurex probably did retain all rights to imaging and Histo-RECAF. kag

http://findarticles.com/p/articles/mi_m0EIN/is_2005_March_31/ai_n13493153/pg_2